Literature DB >> 1993853

Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000.

L B Jaques1, L M Hiebert, S M Wice.   

Abstract

Heparin, hydrogenated dextran sulfate 8000 (Usherdex 8), and dextran sulfate 8000 were administered to rats, and the total drug was separated and determined in endothelium and plasma. A large amount of each drug was recovered from endothelium 2.4 and 6 minutes after intravenous injection. This accounted for the drug missing from plasma. The drugs in water were placed in the stomach by catheter. All three drugs were recovered from the endothelium and identified unchanged by electrophoresis and specific staining. The amounts that were recovered at 2.4 and 6 minutes were equivalent to most of the drug administered. Thus heparin, Usherdex 8, and dextran sulfate 8000 enter the body immediately on oral administration. At longer time intervals after intravenous and oral administration, much of each drug was not demonstrable in endothelium by the method used. Some drug could be detected in endothelium after 4 hours. After oral administration, plasma levels of each drug were rarely more than 0.5% of the dose. Formalin-alcohol was applied to the jugular veins of anesthetized rats to produce a thrombus, (see Blake et al. J Clin Path 1959;12:118-22) and the drugs were immediately introduced into the stomach. Four hours later the injured veins were inspected for thrombi. Incidence of thrombotic plug was 80% in rats that received saline solution, 4% with Usherdex 8, 0% with dextran sulfate 8000, and 0% with heparin. Usherdex 8, dextran sulfate 8000, and heparin demonstrate low, moderate, and high in vitro anticoagulant activity, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993853

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Heparin for oral use: preliminary studies.

Authors:  O Horwitz; W T Johnson; J J Sayen; B Roberts; A F Whereat
Journal:  Trans Am Clin Climatol Assoc       Date:  1993

2.  In vivo antithrombotic synergy of oral heparin and arginine: endothelial thromboresistance without changes in coagulation parameters.

Authors:  Bruce Daniels; Robert J Linhardt; Fuming Zhang; Wenjun Mao; Sandra M Wice; Linda M Hiebert
Journal:  Thromb Haemost       Date:  2006-05       Impact factor: 5.249

3.  Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway.

Authors:  Joseph D Raffetto; Fiorella Calanni; Paolo Mattana; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2019-04-20       Impact factor: 5.858

4.  Tissue distribution of [14C]sucrose octasulfate following oral administration to rats.

Authors:  Linda M Hiebert; Sandra M Wice; Tidly Ping; Ronald E Hileman; Tfilay Polat; Robert J Linhardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

5.  Dextran sulfate protects porcine but not bovine cultured endothelial cells from free radical injury.

Authors:  Jason I Ram; Linda M Hiebert
Journal:  Can J Vet Res       Date:  2003-05       Impact factor: 1.310

6.  Movement of heparins across rat gastric mucosa is dependent on molecular weight and pH.

Authors:  Bita Moazed; Linda M Hiebert
Journal:  Pharm Res       Date:  2008-10-21       Impact factor: 4.200

7.  Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects.

Authors:  Shaker A Mousa; Fuming Zhang; Ahmad Aljada; Seema Chaturvedi; Majde Takieddin; Haifeng Zhang; Lianli Chi; M Cristina Castelli; Kristen Friedman; Michael M Goldberg; Robert J Linhardt
Journal:  J Clin Pharmacol       Date:  2007-12       Impact factor: 3.126

8.  Use of sulodexide in patients with peripheral vascular disease.

Authors:  J Lasierra-Cirujeda; P Coronel; Mj Aza; M Gimeno
Journal:  J Blood Med       Date:  2010-06-15

9.  Sulodexide Improves Contraction and Decreases Matrix Metalloproteinase-2 and -9 in Veins Under Prolonged Stretch.

Authors:  Joseph D Raffetto; Wentao Yu; Xi Wang; Fiorella Calanni; Paolo Mattana; Raouf A Khalil
Journal:  J Cardiovasc Pharmacol       Date:  2020-03       Impact factor: 3.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.